# Safety and Efficacy of Venetoclax, Cytarabine and Metformin (VenCM) for Relapsed-Refractory and Induction-Ineligible Acute Myeloid Leukemia

> **NCT06537843** · PHASE2 · RECRUITING · sponsor: **Hospital Municipal São José** · enrollment: 100 (estimated)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Venetoclax
- **DRUG:** Cytarabine Injection
- **DRUG:** Metformin

## Key facts

- **NCT ID:** NCT06537843
- **Lead sponsor:** Hospital Municipal São José
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-12-01
- **Primary completion:** 2026-07-01
- **Final completion:** 2028-07-01
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2024-08-05

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06537843

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06537843, "Safety and Efficacy of Venetoclax, Cytarabine and Metformin (VenCM) for Relapsed-Refractory and Induction-Ineligible Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06537843. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*